1) Welcome to our #accredited#tweetorial on optimal mgt of #hyperkalemia in the patient with #CKD. Earn 0.5h #CME/CE credit by following this thread. I am Sourabh Sharma MD DNB FASN 🇮🇳 @iamnephrologist & u have found the ONLY source for CE credit delivered entirely on Twitter!
4) Re potassium #homeostasis: 98% of the body's K lies in intracellular space➡️ helping determine resting membrane potential & intracellular electronegativity.
10% of K secretion is via the colon (↑significantly in advancing CKD) 🔓kidney360.asnjournals.org/content/1/1/65#NephroNotes
6) Arrhythmia in Hyperkalemia
Moderate HyperK: Fast Na channel activation; ↑excitability/conduction velocity: Peaked T
Severe HyperK: Fast Na channel inactivation/Inwardly rectifying K channel activation: Wide QRS/Conduction block
🔓academic.oup.com/ndt/article/34…
11) A low-K diet is generally recommended in advanced #CKD, but @goKDIGO suggests interventional trials to determine optimal recommendations, as there is no direct evidence to link dietary K & serum K, and the benefits of K can’t be ignored
🔓kidney360.asnjournals.org/content/1/1/65 #NephroNotes
15) So when hyperK happens, how is it treated? Acutely:
👉IV calcium ↓cardiac membrane excitation (1-3 min)
👉Insulin/glucose & β agonist redistribute K to ICS (30-60 min) but not ↓total body K
👉β Agonists: short duration of effect (2-4hrs)
👉Sodium bicarbonate ↑K elimination
21) So now let's look at oral potassium binders, which are more useful in chronic mgt & can help facilitate #RAASi optimization. Which of the following binders has the most rapid onset of action after oral administration?
24) We were about to start talking about the oral K binders. (BTW earn MORE CE/#CME on this topic at cardiometabolic-ce.com/category/hyper…) Yes, prune juice is a K binder, but it's not quick, & it may make a bigger mess than Na polystyrene sulfonate. So the correct answer was D. More to learn!
27) Start w/the old. Sodium/Calcium Polysterene Sulfonate clinical studies:
👉Limited evidence for effectiveness/safety
👉With sorbitol, can cause colonic necrosis
👉Nonselective for K, with affinity for Ca/Mg ions
👉Caution: Na & volume overload
🔓frontiersin.org/articles/10.33…
28) And then the new. First, #patiromer sorbitex calcium clinical studies:
👉Efficacy established in randomized, placebo-controlled, phase 2 and 3 trials (CKD/ HF/RAASi)
👉Onset of action~ 7 hours
👉No serious AEs
🔓frontiersin.org/articles/10.33… #NephPearls#FOAMed#MedEd
29) Sodium Zirconium Cyclosilicate (#SZC) clinical studies:
👉Efficacy & safety established in Ph 2 & 3 trials (#CKD/#HF/#DM/#RAASi)
👉assoc'd w/ ↑Bicarbonate
👉High selectivity for K & ammonium ions
👉fast onset, starts in small bowel
👉No serious AEs
🔓frontiersin.org/articles/10.33…
31) Treatment of #Hyperkalemia in #hemodialysis patients:
👉Hyperkalaemia contributes to mortality in HD (3-5% deaths)
👉K ⤴️is most common immediately post 3-day weekend break
👉Adjust dialysate K as per 🔓ukkidney.org/sites/renal.or…
32) In summary, the treatment of hyperkalemia is likely to evolve in the coming years with the availability of novel drugs & the development of new strategies to improve safety. Clinical decisions on when to treat & how aggressively to treat require a pt-centered approach ...
33) ... guided by the clinical setting and rate of change in serum K+ level. Patients with moderate levels of hyperkalemia pose the greatest dilemma, especially when acuity is low, but warrant intervention to avoid deterioration.
34) Severe hyperkalemia risks arrhythmias & cardiac arrest, therefore prompt recognition and intervention is required. How big a problem is it? In-hospital mortality is significantly higher in patients w/ hyperkalaemia (X%) hypokalaemia (Y%) vs normokalaemia (Z%). What are X,Y,Z?
35) Per NICE guidelines, the correct answer is B, more exactly hyperkalemia (18.1%) compared to those with hypokalemia (5.0%) or normokalemia (3.9%). Pts with severe hyperK (> 6.5 mmol/l) are most at risk & in one report (🔓pubmed.ncbi.nlm.nih.gov/23171442/ ), hospital mortality was 30.7%.
1) Welcome to a new #accredited #tweetorial from the partnership of @ckd_ce and @ISNeducation. This tweetorial has been prepared by @Dilushiwijay and provides 0.75hr CE/#CME.
2) Statement of accreditation and author disclosures can be found at . No industry funding was provided for this program, which is accredited by @academiccme.
So . . .
How much do you know about #IgAN? 🤔ckd-ce.com/disclosures/
3) Which of these statements about #IgAN is FALSE?
A. It is the most common primary glomerulonephritis
B. It is benign
C. It has a heterogenous presentation
D. It is characterized by dominant or co-dominant IgA staining on biopsy
1) Welcome to this #accredited#tweetorial on genetic testing in the evaluation of patients with cystic kidney disease. #Kidney#cysts are a frequent finding, ranging from simple cysts to suspected or confirmed #ADPKD.
Expert author @dguerrot of @CHURouen 🇫🇷 leads us!
2) This #accredited#tweetorial series on #kidneydisease#CKD is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance. It is not intended for US- or UK-based HCPs. Accreditation statement & faculty disclosures at ckd-ce.com/disclosures/.
1) Welcome to this new #accredited#tweetorial on “Strategies to Apply Current Clinical Trial Data for SGLT2i to Reduce the Progression of CKD,” authored by our ⭐️tweetorialist Edgar V. Lerma 🇵🇭 @edgarvlermamd
2) She is a member of UKCPA Diabetes & Endocrinology committee @UKCPADiabetes & works across #diabetes, #endocrinology, & emergency/acute care in Secondary Care. She is currently involved in development of regional guidelines & education to support medicines optimisation for PLWD
3a) This program is intended for healthcare professionals and is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly Company.
2) This #accredited#tweetorial series on the foundations of #kidneydisease#DKD through the lens of #T2D is supported by an independent educational grant from the Boehringer Ingelheim/Lilly Alliance and is intended for healthcare providers.